Cytokinetics(CYTK)
SOUTH SAN FRANCISCO, CA
Biotechnology1 H-1B visas (FY2023)Focus: Small Molecules
Cytokinetics is a life sciences company focused on Small Molecules.
CardiovascularNeurologyOncologyRare DiseasesRespiratory
Funding Stage
PUBLIC
Open Jobs
19
Products & Portfolio (1)
Pipeline & Clinical Trials
None - observational study
Hypertrophic Cardiomyopathy (HCM)Clinical Trials (1)
NCT07054073HCMR Re-Imaging Study
N/ACK-4021586
Healthy ParticipantsClinical Trials (1)
NCT05877053A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
Phase 1placebo
Heart FailureClinical Trials (1)
NCT01380223A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
Phase 1CK-3828136
Healthy ParticipantsClinical Trials (1)
NCT05662215A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
Phase 1Ispinesib
Breast NeoplasmsClinical Trials (1)
NCT00607841A Study of Ispinesib in Metastatic Breast Cancer
Phase 1Omecamtiv mecarbil
Healthy VolunteerClinical Trials (1)
NCT02601001Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
Phase 1CK-3773274 - Granules in Capsule
Symptomatic Obstructive Hypertrophic CardiomyopathyClinical Trials (1)
NCT03767855A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
Phase 1Omecamtiv Mecarbil
QT Intervals ChangesClinical Trials (1)
NCT04175808Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
Phase 1Aficamten
Healthy ParticipantsClinical Trials (1)
NCT05924815Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Phase 1AMG 423
Heart FailureClinical Trials (1)
NCT01737866Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency
Phase 1CK-3773274
Obstructive Hypertrophic CardiomyopathyClinical Trials (1)
NCT04783766Safety, Tolerability and Pharmacokinetics Study of CK-3773274
Phase 1reldesemtiv
Mobility LimitationSB-743921
Non-Hodgkin's LymphomaClinical Trials (1)
NCT00343564A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Phase 1/2Omecamtiv mecarbil
Heart FailureClinical Trials (1)
NCT01077167Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
Phase 2Reldesemtiv
Chronic Obstructive Pulmonary Disease (COPD)25 mg Omecamtiv Mecarbil
Heart Failure With Reduced Ejection FractionClinical Trials (1)
NCT02695420Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
Phase 2CK-2017357
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT01486849Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2Placebo
Spinal Muscular AtrophyPlacebo
Heart FailureClinical Trials (1)
NCT01300013Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
Phase 2Placebo
Myasthenia GravisClinical Trials (1)
NCT01268280Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Phase 2Omecamtiv Mecarbil Matrix F1 Formulation
Modified Release Oral FormulationClinical Trials (1)
NCT01786512COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
Phase 2CK-1827452 24mg and 6 mg iv infusion
Heart FailureClinical Trials (1)
NCT00682565PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
Phase 2CK-1827452
Heart FailureClinical Trials (1)
NCT00624442A Study of CK-1827452 Infusion in Stable Heart Failure
Phase 2Phase 2
Clinical Trials (1)
NCT01378676A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2CK-1827452
Heart FailureClinical Trials (1)
NCT00748579Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
Phase 2CK-2017357
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT01709149Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
Phase 2Placebo
Intermittent ClaudicationClinical Trials (1)
NCT01131013A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
Phase 2Reldesemtiv
Amyotrophic Lateral SclerosisPhase 2
Clinical Trials (1)
NCT06793371AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Phase 2CK-3773274
Hypertrophic Cardiomyopathy (HCM)Clinical Trials (1)
NCT04219826Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
Phase 2Phase 2
Clinical Trials (1)
NCT01089010A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2CK-1827452
Heart FailureClinical Trials (1)
NCT00941681Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure
Phase 2Aficamten
PediatricClinical Trials (1)
NCT06412666A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Phase 2/3Phase 2/3
Clinical Trials (1)
NCT04848506Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Phase 2/3Phase 3
Clinical Trials (1)
NCT05186818Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Phase 3Reldesemtiv
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT04944784A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 3Reldesemtiv
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT05442775A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Phase 3Omecamtiv Mecarbil
Heart FailureClinical Trials (1)
NCT02929329Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
Phase 3Phase 3
Phase 3
Tirasemtiv
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT02496767Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
Phase 3Omecamtiv Mecarbil
Heart Failure With Reduced Ejection FractionClinical Trials (1)
NCT03759392Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
Phase 3tirasemtiv
Amyotrophic Lateral Sclerosis (ALS)Clinical Trials (1)
NCT02936635A Study for Patients Who Completed VITALITY-ALS (CY 4031)
Phase 3Omecamtiv mecarbil
Chronic Heart Failure With Reduced Ejection FractionClinical Trials (1)
NCT04464525Omecamtiv Mecarbil Post-trial Access Study
Phase 3Omecamtiv Mecarbil
Heart FailureClinical Trials (1)
NCT06736574Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Phase 3Open Jobs (19)
Contract Clinical Systems Specialist
Yesterday
$75 - $86/hr
Associate Director, Clinical Quality Assurance Auditor
4d ago
$195K - $228K/yr
Contract Clinical Systems Manager
5d ago
$120/hr
Head of Clinical Pharmacology
South San Francisco, California
6d ago
$290K - $357K/yr
Senior Manager, Regulatory Writing
Medical Writing
1w ago
$174K - $203K/yr
Senior Director, Investor Relations
South San Francisco, California
Business Development1w ago
$269K - $314K/yr
Senior Manager, Supply Chain & Technical Project Management
Radnor, Pennsylvania
Supply Chain1w ago
$154K - $180K/yr
Senior Director, Legal Counsel (Commercial)
Radnor, Pennsylvania
Commercial1w ago
$275K - $320K/yr
Senior Manager, Supply Chain & Technical Project Management
South San Francisco, California
Supply Chain1w ago
$182K - $212K/yr
Associate Scientist
South San Francisco, California
Research & Development2w ago
$122K - $142K/yr
Contract – Stationary Engineer
South San Francisco, California
3w ago
$50 - $60/hr
Senior Manager, Healthcare Compliance
South San Francisco, California
1mo ago
$176K - $205K/yr
Senior GL Accountant
South San Francisco, California
1mo ago
$139K - $162K/yr
Executive Assistant, Research
South San Francisco, California
1mo ago
$129K - $150K/yr
Vice President, Clinical Operations
South San Francisco, California
1mo ago
$350K - $390K/yr
Associate Director, Clinical Compliance & Training
South San Francisco, California
1mo ago
$196K - $229/yr
Associate Medical Director, Clinical Research Cardiovascular
2mo ago
$232K - $271K/yr
Director, Corporate Securities & Governance Counsel
South San Francisco, California
2mo ago
$302K/yr
Senior Director, Legal Counsel
South San Francisco, California
3mo ago
$333K - $368K/yr
Interview Prep Quick Facts
Portfolio: 1 approved product, 43 clinical trials
Top TAs: Cardiovascular, Neurology, Oncology
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 19 active jobs
Portfolio Health
Launch1 (100%)
1 total products
Therapeutic Area Focus
Marketed
Pipeline
Financials (FY2025)
Revenue
$8M92%
R&D Spend
$330M(4384%)37%
Net Income
-$526MCash
$95MHiring Trend
Stable
19
Open Roles
+4
Added
-2
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub